8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(D)

OF THE SECURITIES EXCHANGE ACT OF 1934

DATE OF REPORT (DATE OF EARLIEST EVENT REPORTED): October 28, 2020

Commission File Number: 0-24260

AMEDISYS, INC.

(Exact Name of Registrant as specified in its Charter)

Delaware	11-3131700
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	AMED	The NASDAQ Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

SECTION 2 — FINANCIAL INFORMATION

ITEM 2.02. RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On October 28, 2020, Amedisys, Inc. (“we,” “us,” “our” or the “Company”) issued a press release announcing its financial results for the three and nine-month periods ended September 30, 2020. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

The information presented in Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered “filed” under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act of 1933, as amended (the “Securities Act”), or the Exchange Act.

SECTION 7 – REGULATION FD

ITEM 7.01. REGULATION FD DISCLOSURE

Item 2.02 of this Current Report on Form 8-K is incorporated herein by reference.

In addition, a copy of the supplemental slides which will be discussed during the Company’s earnings call at 11:00 a.m. ET on Thursday, October 29, 2020 is attached to this report as Exhibit 99.2 and incorporated herein by reference.

The information presented in Item 7.01 of this Current Report on Form 8-K and Exhibit 99.2 attached hereto shall not be deemed “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, unless we specifically state that the information is to be considered “filed” under the Exchange Act or specifically incorporate it by reference in any filing under the Securities Act or the Exchange Act.

SECTION 9 – FINANCIAL STATEMENTS AND EXHIBITS

ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits.

99.1	Press release dated October 28, 2020 announcing the Company’s financial results for the three and nine-month periods ended September 30, 2020 (furnished only)
99.2	Supplemental slides provided in connection with the third quarter 2020 earnings call of the Company (furnished only)
104	Cover Page Interactive Date File (embedded within the Inline XBRL document)

Signatures

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

AMEDISYS, INC. (Registrant)
By:	/s/ Scott G. Ginn
	Scott G. Ginn
	Chief Financial Officer
	(Principal Financial Officer)

DATE: October 28, 2020

EX-99.1

Exhibit 99.1

AMEDISYS REPORTS THIRD QUARTER 2020 FINANCIAL RESULTS

UPDATES 2020 GUIDANCE

BATON ROUGE, Louisiana (October 28, 2020) — Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2020.

Three-Month Periods Ended September 30, 2020 and 2019

• Net service revenue increased $49.5 million to $544.1 million compared to $494.6 million in 2019.

• Net income attributable to Amedisys, Inc. of $72.0 million compared to $34.1 million in 2019.

• Net income attributable to Amedisys, Inc. per diluted share of $2.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) compared to $1.03 in 2019.

Adjusted Quarterly Results*

• Adjusted EBITDA of $75.7 million compared to $56.8 million in 2019.

• Adjusted net service revenue of $544.1 million compared to $494.6 million in 2019.

• Adjusted net income attributable to Amedisys, Inc. of $74.6 million compared to $37.9 million in 2019.

• Adjusted net income attributable to Amedisys, Inc. per diluted share of $2.24 (inclusive of $0.72 income tax benefit related to executive stock option exercise) compared to $1.15 in 2019.

Nine-Month Periods Ended September 30, 2020 and 2019

• Net service revenue increased $65.9 million to $1,520.8 million compared to $1,454.9 million in 2019.

• Net income attributable to Amedisys, Inc. of $138.5 million compared to $99.2 million in 2019.

• Net income attributable to Amedisys, Inc. per diluted share of $4.16 (inclusive of $0.72 income tax benefit related to executive stock option exercise) compared to $3.01 in 2019.

Adjusted Year to Date Results*

• Adjusted EBITDA of $195.4 million compared to $173.0 million in 2019.

• Adjusted net service revenue of $1,520.8 million compared to $1,460.9 million in 2019.

• Adjusted net income attributable to Amedisys, Inc. of $153.9 million compared to $114.2 million in 2019.

• Adjusted net income attributable to Amedisys, Inc. per diluted share of $4.63 (inclusive of $0.72 income tax benefit related to executive stock option exercise) compared to $3.47 in 2019.

* See pages 13-15 for the definition and reconciliations of non-GAAP financial measures to GAAP measures.

Paul B. Kusserow, President and Chief Executive Officer stated, “I am very proud of our third quarter results which have bested both our internal and external expectations and have allowed us to increase our full year 2020 guidance ranges. Home health and hospice have shown strong recoveries and returned to growth this quarter which is no small feat given the continued impact of COIVD-19. We are well underway with our integration of Aseracare, have paid down a large portion of our already low debt and continue to drive prodigious amounts of cash flow. Most importantly, we have done all of this while delivering the highest quality care and continuing our relentless focus on clinical quality. The importance of caring for people in their homes, wherever they call home, has never been more evident, and as such, we are well positioned for continued success. A special thank you to all of our clinician staff for continuing to do what you do best. It is because of your compassion, bravery and tireless efforts that we are able to deliver another great quarter.”

1

Updated 2020 Guidance

• Net service revenue is anticipated to be in the range of $2.067 billion to $2.072 billion.

• Adjusted EBITDA is anticipated to be in the range of $269 million to $272 million.

• Adjusted diluted earnings per share is anticipated to be in the range of $6.02 to $6.08 (inclusive of $0.72 income tax benefit related to executive stock option exercise) based on an estimated 33.4 million shares outstanding.

This guidance excludes the effects of any future acquisitions, if any are made.

We urge caution in considering the current trends and 2020 guidance disclosed in this press release. The home health, hospice and personal care industries are highly competitive and subject to intensive regulations, and trends are subject to numerous factors, risks, and uncertainties, some of which are referenced in the cautionary language below and others that are described more fully in our reports filed with the Securities and Exchange Commission (“SEC”) including our Annual Report on Form 10-K for the fiscal year ended December 31, 2019, subsequent Quarterly Reports on Form 10-Q, and current reports on Form 8-K which can be found on the SEC’s internet website, http://www.sec.gov, and our internet website, http://www.amedisys.com.

Earnings Call and Webcast Information

Amedisys will host a conference call on Thursday, October 29, 2020, at 11:00 a.m. ET to discuss its third quarter results. To participate on the conference call, please call before 11:00 a.m. ET to either (877) 524-8416 (Toll-Free) or (412) 902-1028 (Toll). A replay of the conference call will be available through November 29, 2020 by dialing (877) 660-6853 (Toll-Free) or (201) 612-7415 (Toll) and entering conference ID #13712002.

A live webcast of the call will be accessible through our website on our Investor Relations section at the following web address: http://investors.amedisys.com.

Non-GAAP Financial Measures

This press release includes reconciliations of the most comparable financial measures calculated and presented in accordance with accounting principles generally accepted in the U.S. (“GAAP”) to non-GAAP financial measures. The non-GAAP financial measures as defined under SEC rules are as follows: (1) adjusted EBITDA, defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items; (2) adjusted net service revenue, defined as net service revenue excluding certain items; (3) adjusted other operating income, defined as other operating income excluding certain items; (4) adjusted net income attributable to Amedisys, Inc., defined as net income attributable to Amedisys, Inc. excluding certain items; and (5) adjusted net income attributable to Amedisys, Inc. per diluted share, defined as net income attributable to Amedisys, Inc. common stockholders per diluted share excluding certain items. Management believes that these non-GAAP financial measures, when reviewed in conjunction with GAAP financial measures, are useful gauges of our current performance and are also included in internal management reporting. These non-GAAP financial measures should be considered in addition to, and not more meaningful than or as an alternative to the GAAP financial measures presented in this earnings release and the company’s financial statements. Non-GAAP measures as presented herein may not be comparable to similarly titled measures reported by other companies since not all companies calculate these non-GAAP measures consistently.

Additional Information

Amedisys, Inc. (the “Company”) is a leading healthcare at home company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering our patients to manage a chronic disease; or hospice care at the end of life. More than 2,600 hospitals and 67,000 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 21,000 employees in 516 care centers within 39 states and the District of Columbia, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 415,000 patients and clients in need every year. For more information about the Company, please visit: www.amedisys.com.

We use our website as a channel of distribution for important company information. Important information, including press releases, investor presentations and financial information regarding our company, is routinely posted on and accessible on the Investor Relations subpage of our website, which is accessible by clicking on the tab labeled “Investors” on our website home page. Visitors to our website can also register to receive automatic e-mail and other notifications alerting them when new information is made available on the Investor Relations subpage of our website.

2

Forward-Looking Statements

When included in this press release, words like “believes,” “belief,” “expects,” “strategy,” “plans,” “anticipates,” “intends,” “projects,” “estimates,” “may,” “might,” “could,” “would,” “should” and similar expressions are intended to identify forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements involve a variety of risks and uncertainties that could cause actual results to differ materially from those described therein. These risks and uncertainties include, but are not limited to the following: the impact of the novel coronavirus pandemic (“COVID-19”), including the measures that have been and may be taken by governmental authorities to mitigate it, on our business, financial condition and results of operations, changes in or our failure to comply with existing federal and state laws or regulations or the inability to comply with new government regulations on a timely basis, changes in Medicare and other medical payment levels, our ability to open care centers, acquire additional care centers and integrate and operate these care centers effectively, competition in the healthcare industry, changes in the case mix of patients and payment methodologies, changes in estimates and judgments associated with critical accounting policies, our ability to maintain or establish new patient referral sources, our ability to consistently provide high-quality care, our ability to attract and retain qualified personnel, our ability to keep our patients and employees safe, changes in payments and covered services by federal and state governments, future cost containment initiatives undertaken by third-party payors, our access to financing, our ability to meet debt service requirements and comply with covenants in debt agreements, business disruptions due to natural disaster, acts of terrorism, widespread protest or civil unrest, our ability to integrate, manage and keep our information systems secure, our ability to realize the anticipated benefits of acquisitions and changes in law or developments with respect to any litigation relating to the Company, including various other matters, many of which are beyond our control.

Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified, you should not rely on any forward-looking statement as a prediction of future events. We expressly disclaim any obligation or undertaking and we do not intend to release publicly any updates or changes in our expectations concerning the forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based, except as required by law.

Contact:	Investor Contact:	Media Contact:
	Amedisys, Inc.	Amedisys, Inc.
	Nick Muscato	Kendra Kimmons
	Senior Vice President, Finance	Vice President, Marketing & Communications
	(855) 259-2046	(225) 299-3720
	IR@amedisys.com	kendra.kimmons@amedisys.com

3

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

(Amounts in thousands, except per share data)

(Unaudited)

	For the Three-Month Periods Ended September 30,						For the Nine-Month Periods Ended September 30,
	2020			2019			2020			2019
Net service revenue	$	544,070		$	494,631		$	1,520,814		$	1,454,955
Other operating income		4,812			—			27,592			—
Cost of service, excluding depreciation and amortization		297,668			288,708			878,633			854,734
General and administrative expenses:
Salaries and benefits		123,146			99,941			330,329			293,127
Non-cash compensation		7,124			6,298			19,758			18,451
Other		49,348			48,474			142,616			140,284
Depreciation and amortization		8,283			4,366			19,955			12,440
Operating expenses		485,569			447,787			1,391,291			1,319,036
Operating income		63,313			46,844			157,115			135,919
Other income (expense):
Interest income		31			15			258			59
Interest expense		(2,692	)		(3,778	)		(8,675	)		(11,459	)
Equity in earnings from equity method investments		1,435			(812	)		2,399			4,120
Miscellaneous, net		122			1,975			(2,318	)		2,404
Total other expense, net		(1,104	)		(2,600	)		(8,336	)		(4,876	)
Income before income taxes		62,209			44,244			148,779			131,043
Income tax benefit (expense)		10,202			(9,919	)		(9,175	)		(31,105	)
Net income		72,411			34,325			139,604			99,938
Net income attributable to noncontrolling interests		(430	)		(193	)		(1,147	)		(760	)
Net income attributable to Amedisys, Inc.	$	71,981		$	34,132		$	138,457		$	99,178
Basic earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$	2.20		$	1.06		$	4.26		$	3.09
Weighted average shares outstanding		32,662			32,211			32,469			32,096
Diluted earnings per common share:
Net income attributable to Amedisys, Inc. common stockholders	$	2.16		$	1.03		$	4.16		$	3.01
Weighted average shares outstanding		33,260			33,002			33,267			32,944

4

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED BALANCE SHEETS

(Amounts in thousands, except share data)

	September 30, 2020 (unaudited)			December 31, 2019
ASSETS
Current assets:
Cash and cash equivalents	$	112,904		$	30,294
Restricted cash		2,549			66,196
Patient accounts receivable		250,777			237,596
Prepaid expenses		14,906			8,243
Other current assets		30,114			8,225
Total current assets		411,250			350,554
Property and equipment, net of accumulated depreciation of $101,512 and $96,137		24,104			28,113
Operating lease right of use assets		94,273			84,791
Goodwill		931,483			658,500
Intangible assets, net of accumulated amortization of $17,165 and $7,044		84,143			64,748
Deferred income taxes		24,189			21,427
Other assets		33,278			54,612
Total assets	$	1,602,720		$	1,262,745
LIABILITIES AND EQUITY
Current liabilities:
Accounts payable	$	39,037		$	31,259
Payroll and employee benefits		126,543			120,877
Accrued expenses		170,743			137,111
Provider relief fund advance		60,000			—
Current portion of long-term obligations		10,711			9,927
Current portion of operating lease liabilities		30,462			27,769
Total current liabilities		437,496			326,943
Long-term obligations, less current portion		300,576			232,256
Operating lease liabilities, less current portion		62,519			56,128
Other long-term obligations		44,386			5,905
Total liabilities		844,977			621,232
Equity:
Preferred stock, $0.001 par value, 5,000,000 shares authorized; none issued or outstanding		—			—
Common stock, $0.001 par value, 60,000,000 shares authorized; 37,457,444 and 36,638,021 shares issued; and 32,802,785 and 32,284,051 shares outstanding		37			37
Additional paid-in capital		690,099			645,256
Treasury stock, at cost 4,654,659 and 4,353,970 shares of common stock		(318,771	)		(251,241	)
Accumulated other comprehensive income		—			15
Retained earnings		384,840			246,383
Total Amedisys, Inc. stockholders’ equity		756,205			640,450
Noncontrolling interests		1,538			1,063
Total equity		757,743			641,513
Total liabilities and equity	$	1,602,720		$	1,262,745

5

AMEDISYS, INC. AND SUBSIDIARIES

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS AND DAYS REVENUE OUTSTANDING

(Amounts in thousands, except statistical information)

(Unaudited)

	For the Three-Month Periods Ended September 30,						For the Nine-Month Periods Ended September 30,
	2020			2019			2020			2019
Cash Flows from Operating Activities:
Net income	$	72,411		$	34,325		$	139,604		$	99,938
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization		8,283			4,366			19,955			12,440
Non-cash compensation		7,124			6,298			19,758			18,451
Non-cash 401(k) employer match		—			2,859			—			7,545
Amortization and impairment of operating lease right of use assets		10,591			9,519			29,149			27,014
Loss (gain) on disposal of property and equipment		17			8			(77	)		6
Loss on sale of equity method investment		—			—			2,980			—
Write-off of other comprehensive income		—			—			(15	)		—
Deferred income taxes		1,274			11,923			(2,762	)		17,798
Equity in earnings from equity method investments		(1,435	)		812			(2,399	)		(4,120	)
Amortization of deferred debt issuance costs/debt discount		216			220			653			653
Return on equity investment		1,175			2,885			3,919			3,727
Changes in operating assets and liabilities, net of impact of acquisitions:
Patient accounts receivable		(2,511	)		(15,304	)		6,486			(39,469	)
Other current assets		(24,748	)		(1,851	)		(28,217	)		(10,194	)
Other assets		584			258			(91	)		202
Accounts payable		4,825			1,330			(1,627	)		(8,145	)
Accrued expenses		(2,396	)		(1,359	)		25,594			27,903
Other long-term obligations		17,735			(50	)		38,481			(231	)
Operating lease liabilities		(9,211	)		(7,916	)		(25,576	)		(24,116	)
Operating lease right of use assets		(851	)		(868	)		(2,775	)		(2,622	)
Net cash provided by operating activities		83,083			47,455			223,040			126,780
Cash Flows from Investing Activities:
Proceeds from sale of deferred compensation plan assets		73			74			94			287
Proceeds from the sale of property and equipment		—			12			80			158
Purchases of property and equipment		(1,294	)		(3,644	)		(2,995	)		(6,337	)
Investments in equity method investees		—			—			(875	)		(210	)
Proceeds from sale of equity method investment		—			—			17,876			—
Acquisitions of businesses, net of cash acquired		—			(46	)		(299,723	)		(345,460	)
Net cash used in investing activities		(1,221	)		(3,604	)		(285,543	)		(351,562	)
Cash Flows from Financing Activities:
Proceeds from issuance of stock upon exercise of stock options		3,123			2,045			6,070			3,388
Proceeds from issuance of stock to employee stock purchase plan		914			850			2,600			2,384
Shares withheld to pay taxes on non-cash compensation		(47,788	)		(4,895	)		(54,172	)		(9,385	)
Noncontrolling interest distribution		(300	)		(453	)		(672	)		(910	)
Proceeds from borrowings under term loan		—			—			—			175,000
Proceeds from borrowings under revolving line of credit		7,500			8,000			432,000			192,500
Repayments of borrowings under revolving line of credit		(97,500	)		(41,000	)		(357,000	)		(133,000	)
Principal payments of long-term obligations		(2,685	)		(1,543	)		(7,360	)		(3,820	)
Debt issuance costs		—			—			—			(847	)
Provider relief fund advance		(10,000	)		—			60,000			—
Net cash provided by (used in) financing activities		(146,736	)		(36,996	)		81,466			225,310
Net (decrease) increase in cash, cash equivalents and restricted cash		(64,874	)		6,855			18,963			528
Cash, cash equivalents and restricted cash at beginning of period		180,327			13,902			96,490			20,229
Cash, cash equivalents and restricted cash at end of period	$	115,453		$	20,757		$	115,453		$	20,757

6

Supplemental Disclosures of Cash Flow Information:
Cash paid for interest	$	1,610	$	3,569	$	4,902	$	7,756
Cash paid for income taxes, net of refunds received	$	22,137	$	9,807	$	30,290	$	17,656
Cash paid for operating lease liabilities	$	10,062	$	8,784	$	28,351	$	26,738
Cash paid for finance lease liabilities	$	497	$	—	$	1,483	$	792
Supplemental Disclosures of Non-Cash Activity:
Right of use assets obtained in exchange for operating lease liabilities	$	10,982	$	4,635	$	29,876	$	110,304
Right of use assets obtained in exchange for finance lease liabilities	$	335	$	845	$	822	$	1,806
Reductions to right of use assets resulting from reductions to operating lease liabilities	$	360	$	324	$	767	$	1,235
Days revenue outstanding (1)		40.0		44.5		40.0		44.5

(1) Our calculation of days revenue outstanding at September 30, 2020 and 2019 is derived by dividing our ending patient accounts receivable by our average daily patient revenue for the three-month periods ended September 30, 2020 and 2019, respectively.

7

AMEDISYS, INC. AND SUBSIDIARIES

SEGMENT INFORMATION

(Amounts in millions, except statistical information)

(Unaudited)

Segment Information - Home Health

	For the Three-Month Periods Ended September 30,
	2020			2019
Financial Information (in millions):
Medicare	$	222.2		$	211.5
Non-Medicare		103.8			100.0
Net service revenue		326.0			311.5
Other operating income		2.6			—
Cost of service		180.0			188.9
Gross margin		148.6			122.6
Other operating expenses		79.8			76.5
Operating income	$	68.8		$	46.1
Same Store Growth (1):
Medicare revenue		5	%		2	%
Non-Medicare revenue		4	%		16	%
Total admissions		5	%		9	%
Total volume (2)		6	%		6	%
Key Statistical Data - Total (3):
Admissions		85,578			81,937
Recertifications		47,094			43,340
Total volume		132,672			125,277
Medicare completed episodes (6)		77,552			75,807
Average Medicare revenue per completed episode (4) (6)	$	2,886		$	2,836
Medicare visits per completed episode (5) (6)		14.4			16.9
Visiting Clinician Cost per Visit	$	89.10		$	83.68
Clinical Manager Cost per Visit	$	8.91		$	8.09
Total Cost per Visit	$	98.01		$	91.77
Visits		1,836,895			2,057,184

8

	For the Nine-Month Periods Ended September 30,
	2020			2019
Financial Information (in millions):
Medicare	$	619.0		$	644.0
Non-Medicare		300.8			296.2
Net service revenue		919.8			940.2
Other operating income		17.7			—
Cost of service		543.8			562.4
Gross margin		393.7			377.8
Other operating expenses		229.6			224.0
Operating income	$	164.1		$	153.8
Same Store Growth (1):
Medicare revenue		(4	%)		4	%
Non-Medicare revenue		2	%		18	%
Total admissions		(1	%)		7	%
Total volume (2)		2	%		6	%
Key Statistical Data - Total (3):
Admissions		245,880			247,669
Recertifications		135,263			128,496
Total volume		381,143			376,165
Medicare completed episodes (6)		221,848			229,229
Average Medicare revenue per completed episode (4) (6)	$	2,811		$	2,853
Medicare visits per completed episode (5) (6)		15.2			17.1
Visiting Clinician Cost per Visit	$	88.64		$	82.23
Clinical Manager Cost per Visit	$	9.10		$	7.91
Total Cost per Visit	$	97.74		$	90.14
Visits		5,563,992			6,238,758

(1) Same store information represents the percent change in our Medicare, Non-Medicare and Total revenue, admissions or volume for the period as a percent of the Medicare, Non-Medicare and Total revenue, admissions or volume of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

(2) Total volume includes all admissions and recertifications.

(3) Total includes acquisitions and denovos.

(4) Average Medicare revenue per completed episode is the average Medicare revenue earned for each Medicare completed episode of care. Average Medicare revenue per completed episode for the three and nine-month periods ended September 30, 2020 reflects the suspension of sequestration effective May 1, 2020. Additionally average Medicare revenue per completed episode for the nine-month period ended September 30, 2020 reflects the transition to PDGM during the year and therefore includes reimbursement under both the 60-day episode of care (pre-PDGM) payment rate and the 30-day period of care (PDGM) payment rate.

(5) Medicare visits per completed episode are the home health Medicare visits on completed episodes divided by the home health Medicare episodes completed during the period.

(6) Prior year amounts have been recast to conform to the current year calculation.

9

Segment Information - Hospice

	For the Three-Month Periods Ended September 30,
	2020			2019
Financial Information (in millions):
Medicare	$	189.0		$	153.5
Non-Medicare		10.7			8.9
Net service revenue		199.7			162.4
Other operating income		1.7			—
Cost of service		104.1			84.5
Gross margin		97.3			77.9
Other operating expenses		48.4			36.2
Operating income	$	48.9		$	41.7
Same Store Growth (1):
Medicare revenue		3	%		10	%
Hospice admissions		9	%		4	%
Average daily census		—	%		5	%
Key Statistical Data - Total (2):
Hospice admissions		13,026			9,914
Average daily census		13,953			11,565
Revenue per day, net	$	155.57		$	152.67
Cost of service per day	$	81.05		$	79.51
Average discharge length of stay		101			98

	For the Nine-Month Periods Ended September 30,
	2020			2019
Financial Information (in millions):
Medicare	$	516.5		$	430.0
Non-Medicare		29.7			22.6
Net service revenue		546.2			452.6
Other operating income		8.9			—
Cost of service		293.1			245.9
Gross margin		262.0			206.7
Other operating expenses		129.1			100.9
Operating income	$	132.9		$	105.8
Same Store Growth (1):
Medicare revenue		4	%		6	%
Hospice admissions		3	%		5	%
Average daily census		1	%		6	%
Key Statistical Data - Total (2):
Hospice admissions		35,755			30,055
Average daily census		12,841			10,997
Revenue per day, net	$	155.23		$	150.77
Cost of service per day	$	83.29		$	81.92
Average discharge length of stay		98			98

(1) Same store information represents the percent change in our Medicare revenue, Hospice admissions or average daily census for the period as a percent of the Medicare revenue, Hospice admissions or average daily census of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last twelve months and startups that are an expansion of a same store care center.

(2) Total includes acquisitions and denovos.

10

Segment Information - Personal Care

	For the Three-Month Periods Ended September 30,
	2020		2019
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare		18.4		20.7
Net service revenue		18.4		20.7
Other operating income		0.5		—
Cost of service		13.5		15.3
Gross margin		5.4		5.4
Other operating expenses		3.2		3.1
Operating income	$	2.2	$	2.3
Key Statistical Data - Total (1):
Billable hours		673,161		824,251
Clients served		10,153		12,687
Shifts		280,470		370,451
Revenue per hour	$	27.33	$	25.12
Revenue per shift	$	65.59	$	55.90
Hours per shift		2.4		2.2

	For the Nine-Month Periods Ended September 30,
	2020		2019
Financial Information (in millions):
Medicare	$	—	$	—
Non-Medicare		54.8		62.1
Net service revenue		54.8		62.1
Other operating income		1.0		—
Cost of service		41.7		46.4
Gross margin		14.1		15.7
Other operating expenses		9.6		9.5
Operating income	$	4.5	$	6.2
Key Statistical Data - Total (1):
Billable hours		2,067,958		2,506,113
Clients served		14,057		16,134
Shifts		896,141		1,128,920
Revenue per hour	$	26.51	$	24.77
Revenue per shift	$	61.18	$	55.00
Hours per shift		2.3		2.2

(1) Total includes acquisitions.

11

Segment Information - Corporate

	For the Three-Month Periods Ended September 30,
	2020		2019
Financial Information (in millions):
Other operating expenses	$	49.9	$	40.4
Depreciation and amortization		6.7		2.9
Total operating expenses	$	56.6	$	43.3

	For the Nine-Month Periods Ended September 30,
	2020		2019
Financial Information (in millions):
Other operating expenses	$	129.2	$	122.0
Depreciation and amortization		15.2		7.9
Total operating expenses	$	144.4	$	129.9

12

AMEDISYS, INC. AND SUBSIDIARIES

RECONCILIATION OF NON-GAAP FINANCIAL MEASURES TO GAAP MEASURES

(Amounts in thousands)

(Unaudited)

Adjusted Earnings Before Interest, Taxes, Depreciation and Amortization (“Adjusted EBITDA”) Reconciliation:

	For the Three- Month Periods Ended September 30,						For the Nine- Month Periods Ended September 30,
	2020			2019			2020			2019
Net income attributable to Amedisys, Inc.	$	71,981		$	34,132		$	138,457		$	99,178
Add:
Income tax (benefit) expense		(10,202	)		9,919			9,175			31,105
Interest expense, net		2,661			3,763			8,417			11,400
Depreciation and amortization		8,283			4,366			19,955			12,440
Certain items (1)		3,494			5,088			20,843			20,259
Interest component of certain items (1)		(558	)		(451	)		(1,450	)		(1,338	)
Adjusted EBITDA (2) (7)	$	75,659		$	56,817		$	195,397		$	173,044

Adjusted Net Service Revenue Reconciliation:

	For the Three- Month Periods Ended September 30,				For the Nine- Month Periods Ended September 30,
	2020		2019		2020		2019
Net service revenue	$	544,070	$	494,631	$	1,520,814	$	1,454,955
Add:
Certain items (1)		—		—		—		5,993
Adjusted net service revenue (3) (7)	$	544,070	$	494,631	$	1,520,814	$	1,460,948

Adjusted Other Operating Income Reconciliation:

	For the Three- Month Periods Ended September 30,					For the Nine- Month Periods Ended September 30,
	2020			2019		2020			2019
Other operating income	$	4,812		$	—	$	27,592		$	—
Add:
Certain items (1)		(4,812	)		—		(27,592	)		—
Adjusted other operating income (4) (7)	$	—		$	—	$	—		$	—

Adjusted Net Income Attributable to Amedisys, Inc Reconciliation:

	For the Three- Month Periods Ended September 30,				For the Nine- Month Periods Ended September 30,
	2020		2019		2020		2019
Net income attributable to Amedisys, Inc.	$	71,981	$	34,132	$	138,457	$	99,178
Add:
Certain items (1)		2,585		3,765		15,424		14,992
Adjusted net income attributable to Amedisys, Inc. (5) (7)	$	74,566	$	37,897	$	153,881	$	114,170

13

Adjusted Net Income Attributable to Amedisys, Inc. per Diluted Share Reconciliation:

	For the Three- Month Periods Ended September 30,				For the Nine- Month Periods Ended September 30,
	2020		2019		2020		2019
Net income attributable to Amedisys, Inc. common stockholders per diluted share	$	2.16	$	1.03	$	4.16	$	3.01
Add:
Certain items (1)		0.08		0.11		0.46		0.46
Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share (6) (7)	$	2.24	$	1.15	$	4.63	$	3.47

(1) The following details the certain items for the three and nine-month periods ended September 30, 2020 and 2019:

Certain Items:

	For the Three-Month Period Ended September 30, 2020			For the Nine-Month Period Ended September 30, 2020
	(Income) Expense			(Income) Expense
Certain Items Impacting Other Operating Income:
CARES Act & State COVID-19 grants	$	(4,812	)	$	(27,592	)
Certain Items Impacting Cost of Service:
COVID-19 costs		4,389			27,399
Severance - reductions in staffing levels		(550	)		4,633
Certain Items Impacting Operating Expenses:
Acquisition and integration costs		3,626			9,561
COVID-19 costs		322			1,385
Severance - reductions in staffing levels		—			271
Certain Items Impacting Total Other Income (Expense):
Interest component of certain items		558			1,450
Other (income) expense, net		(39	)		3,736
Total	$	3,494		$	20,843
Net of tax		2,585			15,424
Diluted EPS	$	0.08		$	0.46

	For the Three-Month Period Ended September 30, 2019		For the Nine-Month Period Ended September 30, 2019
	(Income) Expense		(Income) Expense
Certain Items Impacting Net Service Revenue:
Contingency accrual	$	—	$	6,541
Planned closures (8)		—		(548	)
Certain Items Impacting Cost of Service:
Planned closures (8)		15		1,172
Certain Items Impacting Operating Expenses:
Planned closures (8)		28		185
Acquisition and integration costs		4,141		14,393
Legal fees - non-routine		397		373
Certain Items Impacting Total Other Income (Expense):
Interest component of certain items		451		1,338
Other (income) expense, net		56		(3,195	)
Total	$	5,088	$	20,259
Net of tax		3,765		14,992
Diluted EPS	$	0.11	$	0.46

14

(2) Adjusted EBITDA is defined as net income attributable to Amedisys, Inc. before provision for income taxes, net interest expense and depreciation and amortization, excluding certain items as described in footnote 1.

(3) Adjusted net service revenue is defined as net service revenue excluding certain items as described in footnote 1.

(4) Adjusted other operating income is defined as other operating income excluding certain items as described in footnote 1.

(5) Adjusted net income attributable to Amedisys, Inc. is defined as net income attributable to Amedisys, Inc. calculated in accordance with GAAP excluding certain items as described in footnote 1.

(6) Adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share is defined as diluted income per share calculated in accordance with GAAP excluding the earnings per share effect of certain items as described in footnote 1.

(7) Adjusted EBITDA, adjusted net service revenue, adjusted other operating income, adjusted net income attributable to Amedisys, Inc. and adjusted net income attributable to Amedisys, Inc. common stockholders per diluted share should not be considered as an alternative to, or more meaningful than, income before income taxes or other measures calculated in accordance with GAAP. These calculations may not be comparable to a similarly titled measure reported by other companies, since not all companies calculate these non-GAAP financial measures in the same manner.

(8) Planned closures consist of in-patient units acquired from Compassionate Care Hospice whose operations ceased in April 2019.

15

EX-99.2

Amedisys Third Quarter 2020 Earnings Call Supplemental Slides October 29, 2020 Exhibit 99.2

This presentation may include forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon current expectations and assumptions about our business that are subject to a variety of risks and uncertainties that could cause actual results to differ materially from those described in this presentation. You should not rely on forward-looking statements as a prediction of future events. Additional information regarding factors that could cause actual results to differ materially from those discussed in any forward-looking statements are described in reports and registration statements we file with the SEC, including our Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, copies of which are available on the Amedisys internet website http://www.amedisys.com or by contacting the Amedisys Investor Relations department at (225) 292-2031. We disclaim any obligation to update any forward-looking statements or any changes in events, conditions or circumstances upon which any forward-looking statement may be based except as required by law. www.amedisys.com NASDAQ: AMED We encourage everyone to visit the Investors Section of our website at www.amedisys.com, where we have posted additional important information such as press releases, profiles concerning our business and clinical operations and control processes, and SEC filings. Forward-looking statements

Q3 2020 Results

Our Key Areas of Focus Strategic areas of focus and progress made during Q3’20 Home Health*: Total same store admissions +5%, Total same store volume +6% Hospice: Admissions +9%, Personal Care: Billable hours / quarter -18% driven by impact of COVID-19 - turnover dropping into Q3 which will result in better ability to grow moving forward 1 Organic Growth Quality: Amedisys Oct’20 preview STARS score of 4.33 (SHP: 4.5 STARS) 95% of care centers at 4+ Stars in the Oct’20 Preview 45 Amedisys care centers rated at 5-Stars in the Oct’20 Preview Hospice quality – outperforming industry average in all hospice item set (HIS) categories 3 Clinical Initiatives Focusing on optimizing RN / LPN & PT / PTA staffing ratios. Current LPN Ratio: 46.7% (vs. 40.6% in 3Q’19) Current PTA Ratio: 49.6% (vs. 43.7% in 3Q’19) 100% of care centers on Medalogix Care as of Aug. 2020 Adjusted staffing levels in June to reflect clinician mix shift and utilization 4 Capacity and Productivity Aseracare acquisition closed 6/1 $235M purchase price ($203M net of tax asset) 44 care centers 14 states $117M annual revenue Technical integration near complete $659 million invested in Hospice segment since Feb. 2019 4 acquisitions ~6,000 ADC 106 care centers ~5,000 employees 5 M&A 2 Recruiting / Retention Targeting industry leading employee retention amongst all employee categories Current total voluntary turnover ~19% Focus on reduction of clinical turnover with emphasis on “early exits” *Note: Home Health same store volume is defined as admissions plus recertifications 2021 proposed Home Health industry rule net +2.6% increase – final rule expected soon 2021 Final Hospice industry rule net +2.4% increase (effective 10/1/20) 6 Regulatory

Highlights and Summary Financial Results (Adjusted): 3Q 2020(1) Home Health total same store volume +6%, total same store admissions +5%; Hospice same store admissions +9% Amedisys Consolidated Revenue Growth: +10% EBITDA: $76M (+33%) EBITDA Margin: 14% (+240 bps) EPS: $2.24 (+95%) - non-cash compensation tax benefit = $0.72 3Q’20 Net debt: $261.3M Net Leverage ratio: 1.1x CFFO: $83.1M Free cash flow (4): $79.2M DSO: 40.0 (vs. Q4’19 of 40.9 and down 2.0 days since Q2) Balance Sheet & Cash Flow 3Q’20 Same Store (2)(3) : Total Volume: +6% Total Admissions: +5% Other Statistics: Revenue per Episode(6): $2,886 (+1.8%) Total Cost per Visit: $96.85 (+5.5%) Medicare Recert Rate: 36.9% Home Health Growth Metrics (5): Billable hours/quarter: -18% Clients served: -20% Personal Care Same Store Volume (3): Admissions: +9% ADC: flat (ADC lags admits) Other Statistics: Revenue per Day: $155.57 (+1.9%) Cost per day: $79.96 (+0.6%) Hospice 3Q’20 3Q’20 3Q’20 Adjusted Financial Results(1) 3Q’20 The financial results for the three-month periods ended September 30, 2019 and September 30, 2020 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Same Store volume – Includes admissions and recertifications. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments. Includes acquisitions. Medicare sequestration suspended 5/1/20

Our revenue sources: 3Q’20 Medicare FFS: Reimbursed over a 30-day period of care Private Episodic: MA and Commercial plans who reimburse us over a 30-day period of care. Generally at rates ~90% – 100% of Medicare Per Visit: Managed care, Medicaid and private payors reimbursing us per visit performed Hospice Per Day Reimbursement: Routine Care: Patient at home with symptoms controlled ~97% of the Hospice care AMED provides, in line with overall hospice industry provision of care Continuous Care: Patient at home with uncontrolled symptoms Inpatient Care: Patient in facility with uncontrolled symptoms Respite Care: Patient at facility with symptoms controlled Home Health: 320 care centers; 33 states & DC Hospice: 182 care centers; 35 states Personal Care: 14 care centers; 3 states Total AMED: 516 care centers; 39 states and D.C.

Home Health and Hospice Segment (Adjusted) – 3Q 2020(1) Revenue per Episode up 1.8% (sequestration suspension benefit $5M) Y/Y CPV up +$5.08 (+5.5%, raises effective 8/1, health insurance, increase in use of contractors, change in visit mix and lower visit volumes) Visits per Episode decreased 2.5 Home Health Highlights Same store admit growth +9% Net revenue per day +1.9% (sequestration suspension benefit $3M, excluding acquisitions) ~$1.1M cap expense for 3Q Q3’20 Acquisition Contribution: Revenue: $33M Segment EBITDA: $4.2M ($2.1M net of corporate) Hospice Highlights The financial results for the three-month periods ended September 30, 2019 and September 30, 2020 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Pre-Corporate EBITDA does not include any corporate G&A expenses. Same store information represents the percent change in volume or admissions for the period as a percent of the volume or admissions of the prior period. Effective July 1, 2019, same store is defined as care centers that we have operated for at least the last 12 months and startups that are an expansion of a same store care center. Average Medicare revenue per completed episode for the three-month period ended September 30, 2020 reflects the suspension of sequestration effective May 1, 2020. Home Health total volume growth +6%; Hospice Admit Growth +9%

General & Administrative Expenses – Adjusted (1,2) Notes: Year over year total G&A as a percentage of revenue increased 200 basis points ($26 million) Year over year G&A increase due to our acquisitions (~$11M), raises, incentive accruals, higher health insurance costs, and investments related to PDGM, partially offset by lower travel and training spend G&A for our Hospice and Corporate segments include $9.3M and $2.1M, respectively, from acquisitions Total G&A as a percentage of revenue increased 110 bps sequentially The financial results for the three-month periods ended September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020 and September 30, 2020 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Adjusted G&A expenses do not include depreciation and amortization. Impacted by COVID-19, acquisitions, incentive compensation costs, and investments to drive volume growth

Components 3Q19 2Q’20 3Q’20 YoY Variance Detail Initiatives Salaries $63.24 $63.03 $64.81 $1.57 YoY increase due to planned wage increases, shift in visit mix and fixed costs (training, PTO, etc.) on lower visits, partially offset by optimization of discipline mix. Sequential increase due to the same drivers, partially offset by a lesser impact of planned wage increases and an additional holiday in Q3. Staffing mix optimization, productivity and scheduling improvement initiatives in place to help overcome salary increases Contractors $2.83 $3.05 $3.69 $0.86 YOY and Sequential increase driven by additional staffing needs due to COVID-19 Focused efforts on filling positions with full-time clinicians Benefits $11.14 $10.20 $12.59 $1.45 YoY and Sequential increase primarily due to health insurance with COVID related cost shift to Q3 Focus on cost containment and spend optimization with specific focus on high cost claims Transportation & Supplies $6.47 $6.89 $6.85 $0.38 *Visiting Clinician CPV $83.68 $83.17 $87.94 $4.26 Clinical Managers $8.09 $9.27 $8.91 $0.82 Fixed cost associated with non-visiting clinicians and planned wage increases: YOY increase driven by lower visit volumes Unit cost reduced as volume increases Total CPV $91.77 $92.44 $96.85 $5.08 Operational Excellence: Home Health Cost Per Visit (CPV)-Adjusted YOY Total CPV impacted by planned wage increases and lower volumes resulting from COVID-19 *Note: Direct comparison with industry competitors CPV calculation $83.68 $83.17 $87.94

Driving Top Line Growth Growth in all three lines of business impacted by COVID-19 but recovering Home Health Total Volume Hospice ADC Personal Care Total Hours / Quarter

Industry Leading Quality Scores Note: Top Competitor Avg weighted by CCN count and includes LHC, Kindred, AFAM, EHC and BKD Metric OCT 19 Release JAN 20 Release APR 20 Release Oct 20 PREVIEW Quality of Patient Care 4.28 4.27 4.26 4.33 Entities at 4+ Stars 88% 86% 86% 92% Metric JUL 19 Release OCT 19 Release JAN 20 Release APR 20 Release Patient Satisfaction Star 3.87 3.97 3.71 3.80 Performance Over Industry +6% +6% +6% +6% Quality of Patient Care (QPC) Patient Satisfaction (PS) Amedisys maintains a 4-Star average in the Oct 2020 HHC preview with 92% of our providers (representing 95% of care centers) at 4+ Stars and 61% of our providers (representing 65% of care centers) at 4.5+ Stars 26 Amedisys providers (representing 45 care centers) rated at 5-Stars in the Oct 2020 HHC preview. CMS will provide an Oct 2020 HHC release. After this, CMS will hold the data constant (i.e., freeze the data) until the Jan 2022 HHC release.

Hospice Quality: Amedisys Hospice Continues to Move Towards Best-in-Class Hospice Quality Hospice Compare HIS and CAHPS reporting currently “frozen” and will resume reporting in Feb 2022

Debt and Liquidity Metrics ~Net leverage ~1.1x Net debt defined as total debt outstanding ($314.2M) less cash ($52.9M). Leverage ratio (net) is defined as net debt divided by last twelve months adjusted EBITDA ($247.6M). Liquidity defined as the sum of cash balance and available revolving line of credit. Cash per 9/30/20 10-Q less Provider relief fund advance (~$60M)

Cash Flow Statement Highlights (1) Q2 and Q3 include benefit of payroll tax deferral (COVID-19 relief) of approximately $20 and $18M Free cash flow defined as cash flow from operations less routine capital expenditures and required debt repayments.

Income Statement Adjustments (1) The financial results for the three-month periods ended September 30, 2019, December 31, 2019, March 31, 2020, June 30, 2020 and September 30, 2020 are adjusted for certain items and should be considered a non-GAAP financial measure. A reconciliation of these non-GAAP financial measures is included in the corresponding 8-K detailing quarterly results for each respective reporting period. Planned closures consist of in-patient units acquired from Compassionate Care Hospice whose operations ceased in April 2019.

2020 Guidance Update

Amedisys 2020 Updated Guidance Ranges Note: Adjusted numbers are ex-CARES Act funds *EPS: Inclusive of $0.72 income tax benefit related to executive stock option exercise Increased Revenue, EBITDA and EPS guidance ranges for FY 2020 2020 Original Guidance 2020 Reinstated Guidance Revenue $2,115M – $2,160M $2,040M - $2,070M Adjusted EBITDA $250M – $260M $245M - $255M Adjusted Earnings per Share $4.90 – $5.13 $4.84 - $5.06 2020 Updated Guidance $2,067M - $2,072M $269M - $272M $6.02 - $6.08*

Reimbursement Outlook Reimbursement Impact for Home Health and Hospice Home Health Hospice 2020 Final Rule (PDGM – Behavioral Assumptions) (4.36%) Estimated AMED-Specific Impact (2.8%) 2020* Market Basket Update 3.0% Productivity / Other Adjustment (0.4) Estimated Industry Impact +2.6% Estimated AMED-Specific Impact +~0.5% Note: AMED impact differs from industry due to patient mix, referral mix and footprint *Hospice rate increase effective October 1, 2019 – majority of rate increase will be passed through to general inpatient & respite facilities resulting in a ~(0.5%) reduction in gross margin percentage Proposed FY’21 Home Health Rule 2021 Estimated Industry Impact +2.6% Final FY’21 Hospice Rule 2021 Estimated Industry Impact (Effective 10/1/2020) +2.4%

Our Path Forward: 2021 & Beyond 2021 & Beyond – The Future Is Very Bright for AMED Entering 2021 with all PDGM cost levers in place Continued strategic acquisitions of Home Health and Hospice assets – Home Health market share absorption strategy delayed until early 2021 due to CARES Act funds FY 2021 Proposed Home Health rule: +2.6% FY 2021 Final Hospice rule: +2.4% FY 2021 – EBITDA contribution from CCH and AseraCare Integration and optimization of AseraCare asset Previously acquired Hospice assets performing near legacy AMED growth and profitability Continued industry consolidation New referral sources and market share opportunities from SNF@Home Continued expansion of Medicare Advantage “gain share” arrangements

XML

Document and Entity Information	Oct. 28, 2020
Cover [Abstract]
Entity Registrant Name	AMEDISYS INC
Amendment Flag	false
Entity Central Index Key	0000896262
Document Type	8-K
Document Period End Date	Oct. 28, 2020
Entity File Number	0-24260
Entity Incorporation State Country Code	DE
Entity Tax Identification Number	11-3131700
Entity Address, Address Line One	3854 American Way
Entity Address, Address Line Two	Suite A
Entity Address, City or Town	Baton Rouge
Entity Address, State or Province	LA
Entity Address, Postal Zip Code	70816
City Area Code	(225) 292-2031 or (800)
Local Phone Number	467-2662
Written Communications	false
Soliciting Material	false
Pre Commencement Tender Offer	false
Pre Commencement Issuer Tender Offer	false
Security 12b Title	Common Stock, par value $0.001 per share
Trading Symbol	AMED
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false